Drug Profile


Alternative Names: INT-1B3

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InteRNA Technologies
  • Class Antineoplastics; MicroRNAs
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatocellular carcinoma; Malignant melanoma

Highest Development Phases

  • Preclinical Hepatocellular carcinoma; Malignant melanoma

Most Recent Events

  • 18 Apr 2018 Pharmacodynamics and adverse events data from preclinical studies in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2018)
  • 18 Apr 2018 InteRNA Technologies plans clinical development in Cancer
  • 20 Jul 2016 INT 1B3 is available for licensing as of 20 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top